Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Loss of Epithelial Membrane Protein 2 Aggravates Podocyte Injury via Upregulation of Caveolin-1.

Xiaoyang Wan | Zhaohong Chen | Won-Il Choi | Heon Yung Gee | Friedhelm Hildebrandt | Weibin Zhou
Journal of the American Society of Nephrology : JASN | 2016

Nephrotic syndrome is a CKD defined by proteinuria with subsequent hypoalbuminemia, hyperlipidemia, and edema caused by impaired renal glomerular filtration barrier function. We previously identified mutations in epithelial membrane protein 2 (EMP2) as a monogenic cause of this disease. Here, we generated an emp2-knockout zebrafish model using transcription activator-like effector nuclease-based genome editing. We found that loss of emp2 in zebrafish upregulated caveolin-1 (cav1), a major component of caveolae, in embryos and adult mesonephric glomeruli and exacerbated podocyte injury. This phenotype was partially rescued by glucocorticoids. Furthermore, overexpression of cav1 in zebrafish podocytes was sufficient to induce the same phenotype observed in emp2 homozygous mutants, which was also treatable with glucocorticoids. Similarly, knockdown of EMP2 in cultured human podocytes resulted in increased CAV1 expression and decreased podocyte survival in the presence of puromycin aminonucleoside, whereas glucocorticoid treatment ameliorated this phenotype. Taken together, we have established excessive CAV1 as a mediator of the predisposition to podocyte injury because of loss of EMP2, suggesting CAV1 could be a novel therapeutic target in nephrotic syndrome and podocyte injury.

Pubmed ID: 26264854

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NIDDK NIH HHS, United States
    Id: DK091405
  • Agency: NIDDK NIH HHS, United States
    Id: DK076683
  • Agency: NIDDK NIH HHS, United States
    Id: RC1 DK086542
  • Agency: NIDDK NIH HHS, United States
    Id: DK081943
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK076683
  • Agency: NIDDK NIH HHS, United States
    Id: R00 DK091405
  • Agency: Howard Hughes Medical Institute, United States
  • Agency: NIDDK NIH HHS, United States
    Id: DK086542
  • Agency: NIGMS NIH HHS, United States
    Id: R01 GM088040
  • Agency: NIDDK NIH HHS, United States
    Id: P30 DK081943
  • Agency: NIDDK NIH HHS, United States
    Id: K99 DK091405
  • Agency: NIGMS NIH HHS, United States
    Id: GM088040

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.